AUG 19, 2026 · PHASE 2 TRIAL
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
ClinicalTrials.gov
This is a registry record of an ongoing Phase 2 single-arm trial with no results posted; it describes planned conduct and endpoints only.
Reported
Planned enrollment48
Study phasePhase 2
Primary outcomeOverall survival rate at 12 months